Nicox: last patient in phase 3b Whistler study

(CercleFinance.com) - Nicox announces that the final patient visit has been completed in the Whistler phase 3b clinical study.


This clinical study aims to evaluate the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in reducing intraocular pressure (IOP).

18 healthy volunteers with ocular hypertension were enrolled in the phase 3b Whistler study.

The aim of this study was to assess the action of NCX 470 on aqueous humor parameters, notably drainage through the trabecular meshwork and episcleral venous pressure.

NCX 470 is a new nitric oxide (NO)-donating bimatoprost eye drop currently in phase 3 clinical development for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.

Copyright (c) 2025 CercleFinance.com. All rights reserved.